219 related articles for article (PubMed ID: 31477253)
1. The Evolution of Target Hemoglobin Levels in Anemia of Chronic Kidney Disease.
Bazeley J; Wish JB
Adv Chronic Kidney Dis; 2019 Jul; 26(4):229-236. PubMed ID: 31477253
[TBL] [Abstract][Full Text] [Related]
2. Is there an established hemoglobin target range for patients undergoing chronic dialysis?
Shah HH; Fishbane S
Semin Dial; 2018 Jul; 31(4):415-419. PubMed ID: 29509320
[TBL] [Abstract][Full Text] [Related]
3. Soluble Fas affects erythropoiesis in vitro and acts as a potential predictor of erythropoiesis-stimulating agent therapy in patients with chronic kidney disease.
Chiloff DM; de Almeida DC; Dalboni MA; Canziani ME; George SK; Morsi AM; El-Akabawy N; Porada CD; Durao MS; Zarjou A; Almeida-Porada G; Goes MA
Am J Physiol Renal Physiol; 2020 Apr; 318(4):F861-F869. PubMed ID: 32003597
[TBL] [Abstract][Full Text] [Related]
4. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
5. An economic evaluation of erythropoiesis-stimulating agents in CKD.
Clement FM; Klarenbach S; Tonelli M; Wiebe N; Hemmelgarn B; Manns BJ
Am J Kidney Dis; 2010 Dec; 56(6):1050-61. PubMed ID: 20932621
[TBL] [Abstract][Full Text] [Related]
6. Canadian Society of Nephrology commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD.
Moist LM; Troyanov S; White CT; Wazny LD; Wilson JA; McFarlane P; Harwood L; Sood MM; Soroka SD; Bass A; Manns BJ
Am J Kidney Dis; 2013 Nov; 62(5):860-73. PubMed ID: 24054466
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Erythropoietin-Stimulating Agents on Health-Related Quality of Life in Anemia of Chronic Kidney Disease: A Systematic Review and Meta-analysis.
Collister D; Komenda P; Hiebert B; Gunasekara R; Xu Y; Eng F; Lerner B; Macdonald K; Rigatto C; Tangri N
Ann Intern Med; 2016 Apr; 164(7):472-8. PubMed ID: 26881842
[TBL] [Abstract][Full Text] [Related]
8. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
Yoshida T; Hayashi M
Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
[TBL] [Abstract][Full Text] [Related]
9. Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial).
Imai E; Maruyama S; Nangaku M; Hirakata H; Hayashi T; Narita I; Kono H; Nakatani E; Morita S; Tsubakihara Y; Akizawa T
Clin Exp Nephrol; 2016 Feb; 20(1):71-6. PubMed ID: 26081567
[TBL] [Abstract][Full Text] [Related]
10. Use of Erythropoietin-Stimulating Agents (ESA) in Patients With End-Stage Renal Failure Decided to Forego Dialysis: Palliative Perspective.
Cheng HW; Chan KY; Lau HT; Man CW; Cheng SC; Lam C
Am J Hosp Palliat Care; 2017 May; 34(4):380-384. PubMed ID: 26718957
[TBL] [Abstract][Full Text] [Related]
11. The Use of Erythropoiesis-Stimulating Agents in Patients With CKD and Cancer: A Clinical Approach.
Thavarajah S; Choi MJ
Am J Kidney Dis; 2019 Nov; 74(5):667-674. PubMed ID: 31395400
[TBL] [Abstract][Full Text] [Related]
12. Protocol of a randomized controlled trial of an erythropoietin stimulating agent decision aid for anemia treatment in kidney disease.
Beach LB; Wild M; Ramachandran G; Ikizler HO; Cavanaugh KL
BMC Nephrol; 2016 Jul; 17(1):86. PubMed ID: 27430294
[TBL] [Abstract][Full Text] [Related]
13. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
Singh AK
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
[TBL] [Abstract][Full Text] [Related]
14. Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines.
Hung SC; Kuo KL; Tarng DC; Hsu CC; Wu MS; Huang TP
Nephrology (Carlton); 2014 Dec; 19(12):735-9. PubMed ID: 25156587
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study.
Martínez-Castelao A; Cases A; Carballada AT; Iranzo JT; Bronsoms J; Vallès-Prats M; Monserrat DT; Jimenez EM;
Nefrologia; 2015; 35(2):179-88. PubMed ID: 26300512
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.
Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Tonelli M; Garg AX; Pellegrini F; Ravani P; Jardine M; Perkovic V; Graziano G; McGee R; Nicolucci A; Tognoni G; Strippoli GF
Ann Intern Med; 2010 Jul; 153(1):23-33. PubMed ID: 20439566
[TBL] [Abstract][Full Text] [Related]
17. New Treatment Approaches for the Anemia of CKD.
Bonomini M; Del Vecchio L; Sirolli V; Locatelli F
Am J Kidney Dis; 2016 Jan; 67(1):133-42. PubMed ID: 26372086
[TBL] [Abstract][Full Text] [Related]
18. Emerging drugs for treatment of anemia of chronic kidney disease.
Magwood JS; Lebby A; Chen B; Kessler S; Norris L; Bennett CL
Expert Opin Emerg Drugs; 2013 Dec; 18(4):421-9. PubMed ID: 24033253
[TBL] [Abstract][Full Text] [Related]
19. Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review.
Spinowitz B; Pecoits-Filho R; Winkelmayer WC; Pergola PE; Rochette S; Thompson-Leduc P; Lefebvre P; Shafai G; Bozas A; Sanon M; Krasa HB
J Med Econ; 2019 Jun; 22(6):593-604. PubMed ID: 30813807
[No Abstract] [Full Text] [Related]
20. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
